The value of vitamin e as a treatment for Alzheimer's disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs

Evidence-Based Medicine

Volumn 19, Issue 4, 2014, Pages 140-

  Corbett, Anne ^a   Ballard, Clive ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; DOPAMINE RECEPTOR STIMULATING AGENT; MEMANTINE;

ALZHEIMER DISEASE; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANTIOXIDANTS; DOPAMINE AGENTS; FEMALE; HUMANS; MALE; MEMANTINE; VITAMIN E;

EID: 84905910641     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/eb-2014-101741     Document Type: Note

References (3)

1. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366:893-903.
2. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22. (Pubitemid 27183651)
3. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-88. (Pubitemid 40958434)